Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
Sponsor: Keymed Biosciences Co.Ltd
Summary
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis
Official title: An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-07-25
Completion Date
2029-07-31
Last Updated
2025-11-26
Healthy Volunteers
No
Conditions
Interventions
CM336 Injection(Low dose group)
subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.
CM336 Injection(High dose group)
subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.
Locations (2)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China